Cannabinoid receptor 2 inverse agon 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cannabidiol (CBD) / Claritas Pharma
NCT03840512: An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

Active, not recruiting
2a
36
RoW
CBD
Kalytera Therapeutics Israel, Ltd.
Prevention aGVHD
11/22
12/22
ACTRN12619000623190: An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.

Recruiting
2
36
 
Kalytera Therapeutics Israel Ltd, Kalytera Therapeutics Israel Ltd.
Acute Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
 
 
Zygel (cannabidiol gel) / Paragon Biosci
ACTRN12621000874819: Clinical study of cannabidiol in children, adolescents and young adults with Fragile X syndrome (RECONNECT)

Recruiting
3
250
 
Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd
Fragile X Syndrome
 
 
2021-002542-33: Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children, adolescents and young adults with a certain hereditary disease called Fragile X Syndrome

Not yet recruiting
3
204
Europe
ZYN002, Transdermal gel
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 gene. FXS is most commonly caused by silencing of the FMR1 gene due to a trinucleotide repeat expansion. In FXS patients, the relative absence of functional FMRP is associated with critical impairments in neurodevelopment and learning, as well as disruption to other neuronal and non-neuronal functions., Fragile X syndrome (FXS) is a rare disease caused by lack of Fragile X Messenger Ribonucleoprotein 1 due to a faulty gene. It mainly causes learning difficulties in patients., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
ZYN2-CL-017, NCT03802799: Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

Enrolling by invitation
2/3
550
Europe, US, RoW
ZYN002 - Cannabidiol Transdermal Gel, Cannabidiol Transdermal Gel
Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
08/27
08/27
ACTRN12618000516280: Clinical study of Cannabidiol in children and adolescents with Developmental and Epileptic Encephalopathy

Recruiting
2
55
 
Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd
Epilepsy, Developmental disability
 
 
ACTRN12618001868279: Clinical study Of caNNabidiol in children and adolesCenTs with Fragile X Open-Label Extension (CONNECT-FX OLE)

Recruiting
2
300
 
Zynerba Pharmaceuticals Pty. Ltd, Zynerba Pharmaceuticals Pty. Ltd.
Fragile X Syndrome
 
 
ACTRN12619000673145: Clinical Study of Synthetic Cannabidiol in Children and Adolescents with 22q11.2 Deletion Syndrome

Recruiting
2
20
 
Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd
Pediatric 22q11.2 deletion syndrome
 
 
ACTRN12621001512819p: A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Symptoms of Painful Osteoarthritis of the Hand

Not yet recruiting
1/2
20
 
Avecho Biotechnology, Lambert Initiative for Cannabinoid Therapeutics
Osteoarthritis of the hand
 
 
ACTRN12621001512819: A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Symptoms of Painful Osteoarthritis of the Hand

Completed
1/2
20
 
Avecho Biotechnology, Lambert Initiative for Cannabinoid Therapeutics
Osteoarthritis of the hand
 
 
ACTRN12617000150347: A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Active, not recruiting
N/A
16
 
Zynerba Pharmaceuticals, Zynerba Pharmaceuticals Ltd.
Fragile X Syndrome
 
 
Respectrum (cannabidiol/palmitoylethanolamide) / SciSparc
NCT05182697: SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Not yet recruiting
N/A
60
RoW
SCI-210, Oral CBD oil
SciSparc, Negev Autism Center Soroka University Medical Center
Autism Spectrum Disorder (ASD)
06/24
12/24
cannabidiol (DehydraTECH-CBD) / Lexaria Biosci
DehydraTECH, NCT06648031: Comparison of the Safety, Efficacy and Pharmacokinetics of -CBD and -GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Recruiting
1
80
RoW
Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide, Arm 4 - Rybelsus medication (semaglutide) alone, Arm 5- Tirzepatide
Lexaria Bioscience Corp.
Type2diabetes
05/25
09/25
NanoCanna (cannabinoid nano) / Aphios
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cannabidiol (CBD) / Claritas Pharma
NCT03840512: An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

Active, not recruiting
2a
36
RoW
CBD
Kalytera Therapeutics Israel, Ltd.
Prevention aGVHD
11/22
12/22
ACTRN12619000623190: An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.

Recruiting
2
36
 
Kalytera Therapeutics Israel Ltd, Kalytera Therapeutics Israel Ltd.
Acute Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
 
 
Zygel (cannabidiol gel) / Paragon Biosci
ACTRN12621000874819: Clinical study of cannabidiol in children, adolescents and young adults with Fragile X syndrome (RECONNECT)

Recruiting
3
250
 
Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd
Fragile X Syndrome
 
 
2021-002542-33: Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children, adolescents and young adults with a certain hereditary disease called Fragile X Syndrome

Not yet recruiting
3
204
Europe
ZYN002, Transdermal gel
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 gene. FXS is most commonly caused by silencing of the FMR1 gene due to a trinucleotide repeat expansion. In FXS patients, the relative absence of functional FMRP is associated with critical impairments in neurodevelopment and learning, as well as disruption to other neuronal and non-neuronal functions., Fragile X syndrome (FXS) is a rare disease caused by lack of Fragile X Messenger Ribonucleoprotein 1 due to a faulty gene. It mainly causes learning difficulties in patients., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
ZYN2-CL-017, NCT03802799: Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

Enrolling by invitation
2/3
550
Europe, US, RoW
ZYN002 - Cannabidiol Transdermal Gel, Cannabidiol Transdermal Gel
Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
08/27
08/27
ACTRN12618000516280: Clinical study of Cannabidiol in children and adolescents with Developmental and Epileptic Encephalopathy

Recruiting
2
55
 
Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd
Epilepsy, Developmental disability
 
 
ACTRN12618001868279: Clinical study Of caNNabidiol in children and adolesCenTs with Fragile X Open-Label Extension (CONNECT-FX OLE)

Recruiting
2
300
 
Zynerba Pharmaceuticals Pty. Ltd, Zynerba Pharmaceuticals Pty. Ltd.
Fragile X Syndrome
 
 
ACTRN12619000673145: Clinical Study of Synthetic Cannabidiol in Children and Adolescents with 22q11.2 Deletion Syndrome

Recruiting
2
20
 
Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd
Pediatric 22q11.2 deletion syndrome
 
 
ACTRN12621001512819p: A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Symptoms of Painful Osteoarthritis of the Hand

Not yet recruiting
1/2
20
 
Avecho Biotechnology, Lambert Initiative for Cannabinoid Therapeutics
Osteoarthritis of the hand
 
 
ACTRN12621001512819: A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Symptoms of Painful Osteoarthritis of the Hand

Completed
1/2
20
 
Avecho Biotechnology, Lambert Initiative for Cannabinoid Therapeutics
Osteoarthritis of the hand
 
 
ACTRN12617000150347: A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Active, not recruiting
N/A
16
 
Zynerba Pharmaceuticals, Zynerba Pharmaceuticals Ltd.
Fragile X Syndrome
 
 
Respectrum (cannabidiol/palmitoylethanolamide) / SciSparc
NCT05182697: SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Not yet recruiting
N/A
60
RoW
SCI-210, Oral CBD oil
SciSparc, Negev Autism Center Soroka University Medical Center
Autism Spectrum Disorder (ASD)
06/24
12/24
cannabidiol (DehydraTECH-CBD) / Lexaria Biosci
DehydraTECH, NCT06648031: Comparison of the Safety, Efficacy and Pharmacokinetics of -CBD and -GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Recruiting
1
80
RoW
Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide, Arm 4 - Rybelsus medication (semaglutide) alone, Arm 5- Tirzepatide
Lexaria Bioscience Corp.
Type2diabetes
05/25
09/25
NanoCanna (cannabinoid nano) / Aphios
No trials found

Download Options